Breast Cancer Research and Treatment

, Volume 147, Issue 3, pp 609–616 | Cite as

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

  • Lu Chen
  • Hannah M. Linden
  • Benjamin O. Anderson
  • Christopher I. Li


Improvement in breast cancer survival has been observed in recent decades in the U.S., but it is unclear if similar survival gains are consistent across breast cancer subtypes, especially with regards to more advanced stages of the disease. Data were from 13 population-based cancer registries participating in the surveillance, epidemiology, and end results (SEER) program, consisting of women between 20 and 79 years of age diagnosed with invasive breast cancer between 1992 and 2008. 2-year (1992–2008) and 5-year (1992–2006) breast cancer cause-specific survival rates were calculated and stratified by estrogen receptor (ER)/progesterone receptor (PR) status, stage, and race. Annual percent changes in survival rates were assessed. From 1992 through 1998–1999, 5- and 2-year cause-specific survival rates significantly improved across ER+/PR+, ER−/PR−, and ER+/PR− subtypes, with an annual increase ranging from 0.5 to 1.0 % in the 5-year rates. From 1998–1999 to 2006, different patterns were observed by ER/PR subtypes with survival rates slightly improving for ER+/PR+, continuing to improve at a rate of 0.5 % per year for ER−/PR−, and dropping 0.3 % annually for ER+/PR−. No significant survival gains were experienced by patients with ER−/PR+ cancer during the study period. In terms of advanced diseases, greatest annual increases in survival rates were seen for patients with stage III–IV ER+/PR+ and ER−/PR− tumors but less progress was observed for advanced ER+/PR− breast cancers. Steady improvements in survival rates for breast cancer have been achieved over the past several decades. However, 5-year survival rates for stage IV disease remained dismally below 20 % for most ER/PR subtypes.


Breast cancer Survival Estrogen receptor Progesterone receptor Time trend 



This work was supported in part by NCI (N01-PC95001). The dataset used for this analysis was obtained from the Surveillance, Epidemiology, and End Results (SEER) Program Public-Use Data (1992-2008), NCI, Department of Cancer Control and Population Sciences, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. The NCI and SEER program were not involved in the design and conduct of this study, in the analysis or interpretation of the data, or in the preparation and review of this article.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Howlader N, Noone AM, Krapcho M, et al (2013) SEER cancer statistics review, 1975–2010. Accessed 14 August 2014
  2. 2.
    Howlader N, Noone AM, Krapcho M, et al (2014) SEER cancer statistics review, 1975–2011. Accessed 14 August 2014
  3. 3.
    Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784–1792PubMedCrossRefGoogle Scholar
  4. 4.
    Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Cancer 100:44–52PubMedCrossRefGoogle Scholar
  5. 5.
    Holleczek B, Brenner H (2012) Trends of population-based breast cancer survival in Germany and the US: decreasing discrepancies, but persistent survival gap of elderly patients in Germany. BMC Cancer 12:317PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Jatoi I, Chen BE, Anderson WF, Rosenberg PS (2007) Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 25:1683–1690PubMedCrossRefGoogle Scholar
  7. 7.
    Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9:R6PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Ademuyiwa FO, Groman A, Hong C-C et al (2013) Time-trends in survival in young women with breast cancer in a SEER population-based study. Breast Cancer Res Treat 138:241–248PubMedCrossRefGoogle Scholar
  9. 9.
    Bartlett JMS, Brookes CL, Robson T et al (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531–1538PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059–1065PubMedCrossRefGoogle Scholar
  11. 11.
    Bleyer A, Welch HG (2012) Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 367:1998–2005PubMedCrossRefGoogle Scholar
  12. 12.
    Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(Suppl 7):vii10–vii14PubMedGoogle Scholar
  13. 13.
    Smith RE, Good BC (2003) Chemoprevention of breast cancer and the trials of the national surgical adjuvant breast and bowel project and others. Endocr Relat Cancer 10:347–357PubMedCrossRefGoogle Scholar
  14. 14.
    National cancer institute adjusted AJCC 6th ed. T, N, M, and stage—SEER documentation. Accessed 23 Jun 2014
  15. 15.
    Statistical research and applications branch NCI jointpoint regression program, Version 4.0.1Google Scholar
  16. 16.
    Kim HJ, Fay MP, Feuer EJMD (2000) Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19:335–351PubMedCrossRefGoogle Scholar
  17. 17.
    Bérubé S, Provencher L, Robert J et al (2007) Quantitative exploration of possible reasons for the recent improvement in breast cancer survival. Breast Cancer Res Treat 106:419–431PubMedCrossRefGoogle Scholar
  18. 18.
    Dawood S, Broglio K, Gonzalez-Angulo AM et al (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26:4891–4898PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer recurrence and 15 year survival:an overview of the randomized trials. Lancet 365:1687–1717CrossRefGoogle Scholar
  20. 20.
    Colozza M, de Azambuja E, Personeni N et al (2007) Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist 12:253–270PubMedCrossRefGoogle Scholar
  21. 21.
    Riley GF, Warren JL, Harlan LC, Blackwell SA (2011) Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. Medicare Medicaid Res Rev 1:E1–E25CrossRefGoogle Scholar
  22. 22.
    Mitri Z, Constantine T, O’Regan R (2012) The HER2 Receptor in Breast Cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012:743193PubMedPubMedCentralGoogle Scholar
  23. 23.
    Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina breast cancer study. JAMA 295:2492–2502PubMedCrossRefGoogle Scholar
  24. 24.
    Hammond MEH, Hayes DF, Wolff AC et al (2010) American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract 6:195–197PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Cano G, Milanezi F, Leitão D et al (2003) Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagn Cytopathol 29:207–211PubMedCrossRefGoogle Scholar
  26. 26.
    Cheang MCU, Treaba DO, Speers CH et al (2006) Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol 24:5637–5644PubMedCrossRefGoogle Scholar
  27. 27.
    Welsh AW, Harigopal M, Wimberly H et al (2013) Quantitative analysis of estrogen receptor expression shows SP1 antibody is more sensitive than 1D5. Appl Immunohistochem Mol Morphol 21:139–147PubMedPubMedCentralGoogle Scholar
  28. 28.
    Arpino G, Weiss H, Lee AV et al (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254–1261PubMedCrossRefGoogle Scholar
  29. 29.
    Yu K-D, Liu G-Y, Di G-H et al (2007) Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients. Breast 16:307–315PubMedCrossRefGoogle Scholar
  30. 30.
    Carlson RW, Hudis CA, Pritchard KI (2006) Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Cancer Netw 4:971–979Google Scholar
  31. 31.
    Hunt BR, Whitman S, Hurlbert MS (2014) Increasing Black:white disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 38:118–123PubMedCrossRefGoogle Scholar
  32. 32.
    Menashe I, Anderson WF, Jatoi I, Rosenberg PS (2009) Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis. J Natl Cancer Inst 101:993–1000PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321PubMedCrossRefGoogle Scholar
  34. 34.
    Gerend MA, Pai M (2008) Social determinants of Black–White disparities in breast cancer mortality: a review. Cancer Epidemiol Biomarkers Prev 17:2913–2923PubMedCrossRefGoogle Scholar
  35. 35.
    Silber JH, Rosenbaum PR, Clark AS et al (2013) Characteristics associated with differences in survival among black and white women with breast cancer. JAMA 310:389–397PubMedCrossRefGoogle Scholar
  36. 36.
    Lepeak L, Tevaarwerk A, Jones N et al (2011) Persistence in breast cancer disparities between African Americans and whites in Wisconsin. WMJ 110:21–25PubMedPubMedCentralGoogle Scholar
  37. 37.
    Jatoi I, Anderson WF, Rao SR, Devesa SS (2005) Breast cancer trends among black and white women in the United States. J Clin Oncol 23:7836–7841PubMedCrossRefGoogle Scholar
  38. 38.
    DeLancey JOL, Thun MJ, Jemal A, Ward EM (2008) Recent trends in Black–White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev 17:2908–2912PubMedCrossRefGoogle Scholar
  39. 39.
    Livaudais JC, Lacroix A, Chlebowski RT et al (2013) Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women’s health initiative. Cancer Epidemiol Biomarkers Prev 22:365–373PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28:4135–4141PubMedCrossRefGoogle Scholar
  41. 41.
    Sail K, Franzini L, Lairson D, Du X (2012) Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethn Health 17:309–323PubMedCrossRefGoogle Scholar
  42. 42.
    Freedman RA, Hughes ME, Ottesen RA et al (2013) Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 119:839–846PubMedCrossRefPubMedCentralGoogle Scholar
  43. 43.
    Lehtimäki T, Lundin M, Linder N et al (2011) Long-term prognosis of breast cancer detected by mammography screening or other methods. Breast Cancer Res 13:R134PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Population Characteristics—SEER registries. Accessed 31 Jan 2013

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Lu Chen
    • 1
    • 3
  • Hannah M. Linden
    • 2
    • 4
  • Benjamin O. Anderson
    • 1
    • 4
  • Christopher I. Li
    • 1
    • 3
  1. 1.Division of Public Health SciencesFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Clinical DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  3. 3.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  4. 4.School of MedicineUniversity of WashingtonSeattleUSA

Personalised recommendations